Trials / Recruiting
RecruitingNCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
A Phase I Dose Finding Study of MB-CART2219.1 Targeting CD19/CD22 in Adult and Pediatric Patients With Relapsed/Refractory B-cell Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T cells targeting CD19 and CD22 | Using the 3+3 design, the following dose levels will be assessed: Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2027-03-01
- Completion
- 2027-06-01
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT07108868. Inclusion in this directory is not an endorsement.